Vygon signs an exclusive agreement with Carmat, the French manufacturer of an orthotopic artificial heart
"We are honored that Carmat has chosen us to develop this new vascular graft, the first of its kind in the world"
"We are honored that Carmat has chosen us to develop this new vascular graft, the first of its kind in the world"
Designed and developed by Carmat, the Aeson heart is the world's first highly hemocompatible, pulsatile and self-regulating bioprosthetic artificial heart. It has the potential to save the lives of thousands of patients on the heart transplant waiting list every year. The device offers patients quality of life and mobility thanks to its ergonomic, portable external power system, which is permanently connected to the implanted prosthesis.
"We are honored that Carmat has chosen us to develop this new vascular graft, the first of its kind in the world," said Ludovic Richard-Vitton, CEO of Vygon. "Carmat is a shining example of French medical innovation and has created a device that can truly save lives. As medical technology specialists, we are proud to join forces with this innovative company."
Source : Andrew Lloyd & Associates
